舍曲林合并小剂量舒必利治疗女性抑郁症60例疗效观察

Clinical observation of sertraline combined with small-dose sulpiride in treatment of 60 female depression patients

目的:探讨舍曲林合并小剂量舒必利静脉滴注治疗女性抑郁症患者的疗效和安全性。方法:将60例女性抑郁症患者随机分为两组,舍曲林治疗8周。研究组患者在疗程前2周合并舒必利静脉滴注,对照组患者仅给予舍曲林。采用汉密尔顿抑郁量表(HAMD)评定临床疗效,不良反应症状量表(TESS)评定不良反应情况。结果:治疗8周末两组患者HAMD评分均下降,差异有统计学意义(P<0.05),显效率差异无统计学意义(P>0.05),但研究组起效较快;两组患者TESS评分差异无统计学意义(P>0.05),不良反应均较轻微。结论:舍曲林合并小剂量舒必利静脉滴注治疗女性抑郁症起效快,安全性高。

Objective：To evaluate clinical efficacy and safety of sertraline combined with small-dose sulpiride infusion therapy for female depression patients. Methods：60 female depression patients were randomly divided into two groups and received sertraline treatment for 8 weeks. The treatment of research group（n = 30） was also combined with small-dose sulpiride infusion therapy for the first 2 weeks,whereas those in control group（n = 30） received sertraline alone. The efficacy was assessed by the Hamilton depression scale（HAMD） and the safety was assessed by the treatment emergent symptom scale（TESS）. Results： 8 weeks after the treatment,the HAMD scores of both group significantly decreased（P〈0. 05）. The overall efficacy between the two groups showed no statistically significant difference（P 〉 0. 05）,but research group took effect more quickly. The side effects were few and the TESS showed no significant difference（P 〉 0. 05）. Conclusions： Sertraline combined with small-dose sulpiride infusion therapy for the female depression patients takes effect more quickly and has a high safety.